Skip to main content
. 2022 Oct 11;25(6):959–970. doi: 10.1007/s11102-022-01280-6

Table 3.

AEs (≥ 2 patients) regardless of study drug relationship reported during the extension phase (n = 16) and AEs of special interest reported during the entire study (n = 19)

All grades
n
Grade ≥ 3
n
AEs regardless of study drug relationship
 Adrenal insufficiency 7 1
 Arthralgia 6 0
 Headache 6 1
 Diarrhea 5 0
 Abdominal pain 4 1
 Urinary tract infection 4 0
 Arthropod bite 3 0
 Blood testosterone increased 3 0
 Edema peripheral 3 0
 Fatigue 3 0
 Hypertension 3 3
 Lipase increased 3 1
 Vertigo 3 0
 Asthenia 2 0
 Blood corticotropin increased 2 0
 Blood pressure increased 2 0
 Dizziness 2 0
 Gastroenteritis 2 1
 Hypokalemia 2 0
 Influenza 2 0
 Insomnia 2 0
 Iron deficiency anemia 2 0
 Musculoskeletal pain 2 0
 Nasopharyngitis 2 0
 Non-cardiac chest pain 2 1
 Pain in extremity 2 0
 Pituitary-dependent Cushing’s syndrome 2 2
 Upper respiratory tract infection 2 0
 Vomiting 2 0
 Vulvovaginal mycotic infection 2 0
 Weight decreased 2 1
 Weight increased 2 0
AEs of special interest
 Related to accumulation of adrenal hormone precursors 12 4
 Related to hypocortisolism 11 2
 Related to arrhythmogenic potential 1 0
 Related to QT prolongation 1 0

A patient with multiple severity grades for an AE is only counted under the maximum grade. Pituitary-dependent Cushing’s syndrome was the preferred term used by investigators to report events of worsening or uncontrolled Cushing’s syndrome